Daxxify
Daxxify is a U.S.-approved botulinum toxin type A product with the nonproprietary name daxibotulinumtoxinA-lanm. Its adult indications cover glabellar lines and cervical dystonia, with separate dosing and clinical evidence for each use. U.S. prescribing information 🔗
It was developed by Revance Therapeutics. Crown Laboratories completed the acquisition in February 2025, and the combined business subsequently adopted the Revance name. These corporate changes are distinct from the product’s approval and clinical evidence. Acquisition announcement 🔗, company name announcement 🔗
Product Identity
Section titled “Product Identity”| Field | Reference point |
|---|---|
| Brand | Daxxify |
| Nonproprietary name | DaxibotulinumtoxinA-lanm |
| Toxin type | Botulinum toxin type A |
| Developer | Revance Therapeutics |
| Label manufacturing statement | Manufactured for Revance Therapeutics, Inc., according to the prescribing information 🔗. |
| Current commercial company | Revance following Crown Laboratories’ 2025 acquisition |
| Formulation context | Contains the RTP004 peptide excipient, as described in the prescribing information 🔗. |
U.S. Label Context
Section titled “U.S. Label Context”Label and clinical sources checked September 16, 2026.
FDA first approved Daxxify for glabellar lines on September 7, 2022 (FDA Drug Trials Snapshot 🔗). Adult cervical dystonia followed on August 11, 2023 (FDA supplement approval letter 🔗).
The current U.S. prescribing information 🔗 covers temporary improvement of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults, and treatment of adult cervical dystonia. These are separate aesthetic and therapeutic indications, as reflected in the U.S. FDA indication matrix.
Those labels make Daxxify more than a purely aesthetic-market entry, but they do not make its units interchangeable with other botulinum toxin products.
Cervical Dystonia Evidence
Section titled “Cervical Dystonia Evidence”ASPEN-1 was a randomized, double-blind, placebo-controlled trial involving 301 adults. The primary endpoint was change in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), which combines severity, disability, and pain, averaged over weeks 4 and 6. Both active treatment groups improved more than placebo. Registration-trial results 🔗
| ASPEN-1 treatment group | Participants | Mean TWSTRS change, averaged over weeks 4 and 6 | Median duration of effect |
|---|---|---|---|
| Daxxify 125 U | 125 | −12.7 points | 24.0 weeks |
| Daxxify 250 U | 130 | −10.9 points | 20.3 weeks |
| Placebo | 46 | −4.3 points | Not included in this duration comparison. |
TWSTRS changes are least-squares means; lower scores indicate improvement. Duration was defined as time to loss of at least 80% of peak improvement, with peak improvement based on the average at weeks 4 and 6. It is not a measure of time completely free of symptoms. The comparison was against placebo, so these results do not establish superiority over another marketed toxin or a universal six-month treatment interval. ASPEN-1 publication 🔗
Indication-Specific Dosing and Safety
Section titled “Indication-Specific Dosing and Safety”The prescribing information 🔗 specifies 40 U for glabellar lines and 125–250 U for cervical dystonia. These are separate label contexts, not interchangeable treatment regimens. Potency units cannot be converted to those of another botulinum toxin product. Unit interpretation explains this product-specific boundary.
The label carries a boxed warning about distant spread of toxin effect, including potentially serious swallowing and breathing difficulties. Its most common cervical-dystonia adverse reactions include headache, injection-site pain and redness, muscular weakness, and upper respiratory tract infection. Pre-existing swallowing or breathing problems matter to safety assessment. Rates from separate product trials do not establish comparative safety. Warnings and adverse reactions 🔗
Formulation and Market Context
Section titled “Formulation and Market Context”The RTP004 peptide is a formulation component, not a separate approved treatment. Formulation differences alone do not establish better safety, lower immunogenicity, or superior duration across indications. Such claims require product- and indication-specific evidence. Formulation description 🔗
The cervical dystonia overview places the product alongside four other U.S.-approved toxin products and compares published market estimates. Those estimates describe a condition-level market, not sales or market share for Daxxify. Aesthetic and therapeutic revenue also require separate interpretation.
Related Products and People
Section titled “Related Products and People”Daxxify sits in the same U.S. type A brand map as Botox, Dysport, Xeomin, Jeuveau, and Letybo. Revance / Crown Laboratories supplies its development and ownership history.
Several people pages separate the main Revance angles: Mark Foley for Daxxify’s approval-period leadership, Nadeem Moiz for current post-acquisition company context, Steve Kreider for commercialization, and Thomas Hitchcock, Ph.D. and Conor Gallagher, Ph.D. for innovation and science framing. Jeff Bedard explains the Crown / Revance acquisition and name-transition period, while Nick Crowe adds post-acquisition operations context. Botulinum toxin type A explains the shared biology, while immunogenicity and diffusion provide caution for common cross-product comparison claims.
The post-acquisition leadership roles are documented in the company’s executive appointments announcement 🔗.